Latest News and Events

GeoVax Reports 2016 Second Quarter Financial Results and Provides Corporate Update
Ongoing Vaccine Programs in Zika, HIV, Hemorrhagic Fevers, Hepatitis B and Cancer GeoVax Labs, In...
Continue Reading...
GeoVax Awarded NIH Contract for up to $7.8 Million to Manufacture HIV Vaccine for Advanced Human Clinical Trials
Supports Production of the DNA Component of GeoVax’s GOVX-B11 Preventive HIV Vaccine GeoVax Labs,...
Continue Reading...
GeoVax Reports Progress with Hemorrhagic Fever Vaccine Program
Vaccine to Address Four Major Hemorrhagic Fever Viruses – Ebola, Sudan, Marburg, and Lassa; VLP P...
Continue Reading...